InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-4.3%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Katabi Maha, Director. Director active across 3 companies, notably Vera Therapeutics, Inc.. Cumulatively, 8 filings have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €5.9m. Activity tracked since 30 January 2024. The latest transaction was disclosed on 21 March 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
32,756 shares@ US$43.0021.8% of flowClass A Common StockSEC:0001104659-24-038589:0
1,209,764 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005511:0
161,290 shares@ US$31.0078.2% of flowClass A Common StockSEC:0001104659-24-009537:0
Ideal exit: 26 Oct 2024 (T+270)
973,653 sharesCommon StockSEC:0001209191-23-050305:0
3,401,544 sharesCommon StockSEC:0001104659-21-089437:0
3,401,544 sharesCommon StockSEC:0001104659-21-089437
2,187,504 sharesClass A Common StockSEC:0001209191-21-033812:0
2,187,504 sharesClass A Common StockSEC:0001209191-21-033812
8 of 8 declarations
About Katabi Maha
Maha Katabi is a Director at Vera Therapeutics, Inc. and Aerovate Therapeutics, Inc. In this role, she contributes to the strategy and governance of the companies. Vera Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases, while Aerovate Therapeutics, Inc. focuses on respiratory therapies. Maha Katabi brings valuable expertise in biotechnology and healthcare.
